Fig. 1 · Structure

Documents & Downloads

Swertiamarin

Cat. No. A12128 CAS 17388-39-5

HMG-CoA reductase inhibitor

Swertiamarin has shown potential as antiatherogenic agent by inhibiting HMG-CoA reductase activity in high cholesterol fed rats.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Swertiamarin Research Summary

This section summarizes 4 in vivo studies of Swertiamarin from 3 published references.

Swertiamarin In Vivo Studies

In male Charles Foster rats in an NIDDM model, Swertiamarin at 50 mg/kg/day p.o. for 40 days reduced serum triglycerides near to control levels compared with DM, reaching 63.34 ± 7.86 mg/dL. Under the same treatment conditions, total cholesterol was 86.75 ± 13.64 mg/dL, with DM as the comparator. In male C57BL/6 mice fed HFD, dietary Swertiamarin at 0.01% (w/w) or 0.1% (w/w) for 8 weeks yielded plasma total cholesterol levels of 93.2 ± 5.7 mg/dL and 68.3 ± 10.4 mg/dL, respectively, compared with 105.4 ± 10.2 mg/dL in the HFD control. In male Wistar rats without CS treatment, oral Swertiamarin at 32 mg/kg/d for 90 days did not increase or decrease Hyp content relative to vehicle control. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Serum Triglycerides in NIDDM Rats

Animal study · Male Charles Foster rats; NIDDM rat model; six rats in each group [1]

Male Charles Foster rats in an NIDDM model received Swertiamarin at 50 mg/kg/day p.o. for 40 days. Compared with DM, serum triglycerides were reduced near to control levels, reaching 63.34 ± 7.86 mg/dL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
serum triglyceride levelsTriglyceride 63.34 ± 7.86 mg/dL[1]

Conditions shared by the study groups

Route
p.o.
Treatment course
40 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Swertiamarin 50 mg/kg/dayDMreduced the serum triglyceride level near to control levels; 63.34 ± 7.86 mg/dL[1]
Swertiamarin 50 mg/kg/day
Model: Male Charles Foster rats; NIDDM rat model; six rats in each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Swertiamarin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Animals and Housing (S15, S17); 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); 3. Results > 3.6. Lipid Profile (S83); Table 2 legend (S133); Table 2 (T2.h1, T2.r1)

serum triglyceride levels: serum triglyceride levels; comparator: DM — 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19); 3. Results > 3.6. Lipid Profile (S83); Table 2 legend (S133); Table 2 (T2.h1, T2.r1)

Swertiamarin 50 mg/kg/day · 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); 3. Results > 3.6. Lipid Profile (S83); Table 2 legend (S133); Table 2 (T2.h1, T2.r1)

Plasma total cholesterol in mice fed HFD

Animal study · Eight-week-old male C57BL/6 mice; HFD (n = 6) [2]

Male C57BL/6 mice fed HFD received dietary Swertiamarin at 0.01% (w/w) or 0.1% (w/w) for 8 weeks. Plasma total cholesterol was 93.2 ± 5.7 mg/dL and 68.3 ± 10.4 mg/dL, respectively, compared with 105.4 ± 10.2 mg/dL in the HFD control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma TC(mg/dL)Plasma TC HFD + 0.01%STM: 93.2 ± 5.7 mg/dL; HFD + 0.1%STM: 68.3 ± 10.4 mg/dL[2]

Conditions shared by the study groups

Route
fed
Treatment course
8 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Swertiamarin 0.01% (w/w); 0.1% (w/w)HFDThe mice were fasted for 16 h. Plasma TC(mg/dL): HFD + 0.01%STM, 93.2 ± 5.7 mg/dL; HFD + 0.1%STM, 68.3 ± 10.4 mg/dL (#p < 0.05 vs. HFD); HFD, 105.4 ± 10.2 mg/dL.[2]
Swertiamarin 0.01% (w/w); 0.1% (w/w)
Model: Eight-week-old male C57BL/6 mice; HFD (n = 6)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Swertiamarin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals and diets (S1); Results > Swertiamarin reduces body weight and alleviates insulin resistance in mice fed a HFD (S53); Figure 1. legend (S158); Figure 2. legend (S159); Table 1. legend (S207, S209); Table 1. (T1.h1, T1.r3)

Plasma TC(mg/dL): Plasma TC(mg/dL); comparator: HFD — Table 1. legend (S207, S209); Table 1. (T1.h1, T1.r3)

Swertiamarin 0.01% (w/w); 0.1% (w/w) · Materials and Methods > Animals and diets (S1); Table 1. legend (S207, S209); Table 1. (T1.h1, T1.r3)

Hyp Content in Rats Without CS Treatment

Animal study · Male Wistar rats; another 6 rats; without CS treatment [3]

Male Wistar rats without CS treatment received Swertiamarin orally at 32 mg/kg/d for 90 days. Hyp content did not increase or decrease compared with vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hyp contentReported result did not increase or decrease (p>0.05)[3]

Conditions shared by the study groups

Route
orally
Treatment course
for 90 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Swertiamarin 32 mg/kg/dvehicle controldid not increase or decrease (p>0.05)[3]
Swertiamarin 32 mg/kg/d
Model: Male Wistar rats; another 6 rats; without CS treatment
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Swertiamarin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Swertiamarin ameliorated CS-induced prostatic collagen deposition (S8); MATERIALS AND METHODS > Rat model of CS exposure (S42, S51)

Hyp content: Hyp content; comparator: vehicle control — RESULTS > Swertiamarin ameliorated CS-induced prostatic collagen deposition (S8)

Swertiamarin 32 mg/kg/d · RESULTS > Swertiamarin ameliorated CS-induced prostatic collagen deposition (S8); MATERIALS AND METHODS > Rat model of CS exposure (S51)

Total Cholesterol in NIDDM Rats

Animal study · Male Charles Foster rats; NIDDM rat model; six rats in each group [1]

Male Charles Foster rats in an NIDDM model received Swertiamarin at 50 mg/kg/day p.o. for 40 days. In the comparison with DM, total cholesterol was reported as 86.75 ± 13.64 mg/dL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total cholesterolTotal cholesterol 86.75 ± 13.64 mg/dL[1]

Conditions shared by the study groups

Route
p.o.
Treatment course
40 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Swertiamarin 50 mg/kg/dayDM86.75 ± 13.64 mg/dL[1]
Swertiamarin 50 mg/kg/day
Model: Male Charles Foster rats; NIDDM rat model; six rats in each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Swertiamarin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Animals and Housing (S15, S17); 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); Table 2 legend (S133); Table 2 (T2.h1, T2.r2)

Total cholesterol: Total cholesterol; comparator: DM — Table 2 legend (S133); Table 2 (T2.h1, T2.r2)

Swertiamarin 50 mg/kg/day · 2. Materials and Methods > 2.3. Dosing of Swertiamarin and Aqueous Extract in NIDDM Rats (S19, S20); Table 2 legend (S133); Table 2 (T2.h1, T2.r2)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 17388-39-5
Applications HMG-CoA reductase inhibitor
Formula C16H22O10
Molecular Weight 374.34
SMILES
C=C[C@H]1[C@@H](OC=C2[C@]1(CCOC2=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 64 mg/mL (170.97 mM)
Ethanol <1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Swertiamarin Research References

  1. [1] Patel TP, Soni S, Parikh P, et al. Swertiamarin: An Active Lead from Enicostemma littorale Regulates Hepatic and Adipose Tissue Gene Expression by Targeting PPAR- γ and Improves Insulin Sensitivity in Experimental NIDDM Rat Model. Evid Based Complement Alternat Med (2013). PMID: 23840254 DOI: 10.1155/2013/358673 Source material
  2. [2] Xu L, Li D, Zhu Y, et al. Swertiamarin supplementation prevents obesity-related chronic inflammation and insulin resistance in mice fed a high-fat diet. Adipocyte (2021). PMID: 33794740 DOI: 10.1080/21623945.2021.1906510 Source material
  3. [3] Chen J, Liu J, Lei Y, et al. The anti-inflammation, anti-oxidative and anti-fibrosis properties of swertiamarin in cigarette smoke exposure-induced prostate dysfunction in rats. Aging (Albany NY) (2019). PMID: 31739286 DOI: 10.18632/aging.102467 Source material

Added to your cart

View Cart Checkout
Loading...